Prime's recent analysis shows that patients with obesity stopped using a GLP-1 medication within the first few years of treatment.

GLP-1 year two cost effectiveness study abstract

Among the key findings from the study — among 4,066 members, Prime/MRx found 1 in 3 stayed on their GLP-1 and 27% took their medication as intended

cover image for the 2025 Spring Prime Therapeutics Report Autoimmune management: Updates and challenges Prime Therapeutics /spring-2025-prime-therapeutics-report The Prime Therapeutics Report is...

publications The evolution of GLP-1s July 31, 2025 Prime's clinical experts share their perspectives on developing a holistic, individualized strategy to capitalize on opportunities and improve...

Forbes: Injectable glucagon-like peptide-1 agonists, or GLP-1s, were first approved as diabetes medications 20 years ago

Experts from AMCP discuss the real-world evidence on GLP-1 usage and health care spending.

David Lassen, vice president of pharmacy clinical services, and Marci Chodroff, vice president and medical director at Prime Therapeutics, share more about the latest GLP-1 insights from ongoing...